BEIGENE
DEAD

Serial Number

90647330

Owner

BeiGene, Ltd.

Attorney

Kristen S. Ruisi

Filing Date

Apr 15, 2021

Add to watchlist:

No watchlists yet
View on USPTO

BEIGENE Trademark

Serial Number: 90647330

BEIGENE is a trademark filed by BeiGene, Ltd. on April 15, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

BeiGene, Ltd. (84 trademarks)

San Mateo, CA 94404

Entity Type: 99

Trademark Details

Filing Date

April 15, 2021

Registration Date

Not Registered

Published for Opposition

October 19, 2021

Goods & Services

Custom manufacturing services in the nature of chemical processing and production of medicines and pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases

Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; medicines for human purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Injectable pharmaceuticals for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude drugs in the nature of pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Biochemical preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases

Telemedicine services; health care; convalescent home services; beauty salon services; physical therapy services; gardening; veterinary services; health counseling; pharmacy advice, namely, pharmaceutical advice; rental of sanitary installations

Research and development of new products for others; technological research in the field of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical research; conducting clinical trials for others for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological research; quality control for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; electronic data storage; material testing; cloud computing featuring software for use in database management, word processing, spreadsheet management, tracking; packaging design

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jan 17, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jan 16, 2023 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 7, 2022 EXRA
SOU EXTENSION 1 GRANTED
Apr 5, 2022 EX1G
SOU EXTENSION 1 FILED
Apr 5, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 5, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 14, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 19, 2021 NPUB
PUBLISHED FOR OPPOSITION
Oct 19, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 29, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 13, 2021 CNSA
ASSIGNED TO EXAMINER
Sep 8, 2021 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jul 23, 2021 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 22, 2021 NWOS
NEW APPLICATION ENTERED
Apr 19, 2021 NWAP